

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (review of TA696) [ID6327]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

At scoping consultation, it was raised that the Val122Ile variant of ATTR-CM is most common in people with African or Caribbean family background. It was also highlighted that this population is often diagnosed later and has worse outcomes than other ATTR-CM patients. The committee acknowledged this but considered that the equalities issues raised were not something that could be addressed in its recommendations.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

The professional group submissions also highlighted the fact that prescribing tafamidis might be restricted to specialist centres and that people with ATTR-CM are often older and could experience difficulties with travelling long distances to have treatment. The committee took these factors into account in its decision making but agreed that this was not something that could be addressed in its recommendation.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

As per question 2, professional group submissions highlighted that the prescribing may be restricted to specialist centres and people with a disability may find it harder to travel long distances as a result of the disability.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No.

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

Yes, see section 3.15

Approved by Associate Director (name): ...Linda Landells.....

Date: 20 February 2024

Final draft guidance

(when DG issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

At Draft guidance consultation stage, consultees reiterated the issue of regional variability in access to tafamidis and the lack of treatment options available to people with wild type ATTR-CM. The committee took the substantial unmet need in this population into account in its decision making.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified

in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?
No

5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?
Yes, please refer to section 3.15

Approved by Associate Director (name): ...Linda Landells.....

Date: 18 April 2024